Sector News

Arbor Pharmaceuticals explores $1 bln-plus sale – sources

October 3, 2014
Life sciences
(Reuters) – Arbor Pharmaceuticals LLC is exploring a sale that could fetch more than $1 billion for the privately-held specialty drugmaker, according to people familiar with the matter.
 
Atlanta, Georgia-based Arbor, which makes prescription drugs for cardiovascular, hospital and pediatric markets, is working with JPMorgan Chase on the potential sale, the people with knowledge of the situation said on Thursday, asking not to be named because the discussions are private.
 
Arbor joins a number of healthcare companies considering a sale at a time when robust buyout appetite from pharmaceutical and biotech companies is driving deal volumes to their highest levels in several years.
 
Representatives for Arbor could not be immediately reached for comment, while JPMorgan declined to comment.
 
The company has branded and generic prescription products for specialty focused conditions in various stages of development, and has 280 sales professionals, according to its website.
 
Its products include Nitrolingual Pumpspray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease; EDARBI for the treatment of high blood pressure in adults; and Zenzedi for the treatment of narcolepsy or attention deficit hyperactivity disorder in pediatric patients. (Reporting by Jessica Toonkel and Soyoung Kim in New York; Editing by Tom Brown)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”